Who are Short Course Adjuvent Chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): oxaliplatin and gemcitabine, docetaxel plus oxaliplatin and capecitabine, induction chemotherapy, Chemotheraoy along, Tri-weekly cisplatin with RT, TLC599.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/short-course-adjuvent-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Short Course Adjuvent Chemotherapy — Competitive Intelligence Brief

Short Course Adjuvent Chemotherapy (Short Course Adjuvent Chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapeutic agent. Area: Oncology.

phase 3 Chemotherapeutic agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Short Course Adjuvent Chemotherapy (Short Course Adjuvent Chemotherapy) — Trans Tasman Radiation Oncology Group. Short Course Adjuvent Chemotherapy involves administering a limited course of chemotherapy to enhance the effectiveness of radiation therapy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Short Course Adjuvent Chemotherapy TARGET	Short Course Adjuvent Chemotherapy	Trans Tasman Radiation Oncology Group	phase 3	Chemotherapeutic agent
oxaliplatin and gemcitabine	oxaliplatin and gemcitabine	Shanghai Zhongshan Hospital	phase 3	Platinum-based chemotherapeutic agent and nucleoside analog
docetaxel plus oxaliplatin and capecitabine	docetaxel plus oxaliplatin and capecitabine	LiNing	phase 3	chemotherapeutic agents
induction chemotherapy	induction chemotherapy	Zhejiang Cancer Hospital	phase 3	Chemotherapeutic agent
Chemotheraoy along	Chemotheraoy along	Fujian Medical University	phase 3	Chemotherapeutic agent
Tri-weekly cisplatin with RT	Tri-weekly cisplatin with RT	Korea Cancer Center Hospital	phase 3	chemotherapeutic agent
TLC599	TLC599	Taiwan Liposome Company	phase 3	chemotherapeutic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapeutic agent class)

All India Institute of Medical Sciences · 1 drug in this class
Fujian Medical University · 1 drug in this class
Trans Tasman Radiation Oncology Group · 1 drug in this class
Zhejiang Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Short Course Adjuvent Chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/short-course-adjuvent-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab